Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Antengene of Shanghai Announces a $21 Million Series A Round

publication date: Aug 16, 2017
Antengene, a one-year-old Shanghai startup, completed a $21 million series A round, led by Qiming Venture Partners. Antengene plans to in-license drugs, ranging from mid-stage development to mature brands, for China and other East Asian markets. Earlier this year, Antengene acquired China/East Asia rights to a Celgene cancer candidate. Also participating in the A round were China VCs TF Capital and HG Capital, along with Tigermed Investment. Tigermed will conduct the China clinical trials of Antengene's lead drug. More details....

Stock Symbol: (NSDQ: CELG)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital